跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
KRAS-G12V
首页
药物
KRAS-G12V
KRAS-G12V
未知生产厂商
订阅
生成 AI 研报
Share to Twitter
Share to Facebook
Share to LinkedIn
Share to Reddit
摘要
临床试验
审批记录
专利
每项发明一条,涵盖美国、欧洲、PCT 与中国的同族专利。
MACROCYCLIC KRAS INHIBITORS AND METHODS OF USE
EP 4598921 A1
申请人: AMGEN INC
优先权: 2022
CN
EP
US
WO
8 件公开
TETRAHYDROPYRIDOPYRIMIDINE PAN-KRAS INHIBITORS
EP 4262803 A4
申请人: MIRATI THERAPEUTICS INC
优先权: 2020
EP
US
WO
7 件公开
EP 4540254 A1
申请人: MIRATI THERAPEUTICS INC
优先权: 2022
CN
EP
US
WO
4 件公开
T CELL RECEPTOR RECOGNISING KRAS MUTATION AND ENCODING SEQUENCE THEREOF
EP 4043486 A4
申请人: XLIFESC LTD
优先权: 2019
CN
EP
US
WO
5 件公开
Screening and antitumor use of KRAS mutation specific T cell receptor
US 12692298 B2
申请人: INST MICROBIOLOGY CAS
优先权: 2020
CN
EP
US
WO
5 件公开
COMPOSITIONS AND METHODS FOR INHIBITION OF KRAS
EP 4565579 A1
申请人: THERAS INC
优先权: 2022
CN
EP
US
WO
5 件公开
HETEROCYCLIC COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH
EP 4568974 A4
申请人: BEONE MEDICINES I GMBH
优先权: 2022
CN
EP
US
WO
5 件公开
EP 4499639 A4
申请人: BEONE MEDICINES I GMBH
优先权: 2022
CN
EP
US
WO
4 件公开
EP 4568973 A4
申请人: BEONE MEDICINES I GMBH
优先权: 2022
CN
EP
US
WO
4 件公开
EP 4568967 A4
申请人: BEONE MEDICINES I GMBH
优先权: 2022
CN
EP
US
WO
4 件公开
WO 2025168072 A1
申请人: BEIGENE SUZHOU CO LTD
优先权: 2024
CN
WO
2 件公开
TCR MOLECULE TARGETING KRAS G12V MUTATION, CELL, AND USES THEREOF
EP 4660206 A1
申请人: BEIJING DCTY BIOTECH CO LTD
优先权: 2023
CN
EP
US
WO
5 件公开
ANTIGEN COMPOSITION FOR INDUCING KRAS-SPECIFIC ACTIVATED T CELLS
WO 2023085657 A1
申请人: MYONGJI HOSPITAL
优先权: 2021
WO
5 件公开
FUSED RING COMPOUND, PHARMACEUTICAL COMPOSITION CONTAINING SAME, AND USE OF FUSED RING COMPOUND
EP 4509507 A4
申请人: CHENGDU HYPERWAY PHARMACEUTICALS CO LTD
优先权: 2022
CN
EP
US
WO
4 件公开
T CELL RECEPTOR TARGETING KRAS G12V MUTANT POLYPEPTIDE, AND USE THEREOF
US 20260174849 A1
申请人: IMMUXELL BIOTECH LTD
优先权: 2022
CN
EP
US
WO
4 件公开
第 1 / 9 页
上一页
下一页
药物
反馈